Preventive and Therapeutic Interventions for Anticancer Drug-induced Dermatologic Toxicities: a Scoping Review Authors: Yohei Iimura, Seiichiro Kuroda Published: 2026 ABSTRACT AbstractPurpose of ReviewAnticancer drug-induced dermatologic toxicities frequently compromise quality of life and treatment adherence. While diverse strategies have been investigated, evidence patterns across drug classes remain unclear. This scoping review aimed to systematically map clinical studies evaluating preventive and therapeutic interventions for dermatological toxicities—specifically EGFR inhibitor-associated rash, capecitabine-induced hand–foot syndrome (HFS), and multikinase inhibitor-associated hand–foot skin reaction (HFSR)—using a mechanism- and outcome-based framework.Recent FindingsBased on the analysis of 51 clinical studies, distinct evidence patterns emerged. For EGFR inhibitor-associated rash, prophylactic strategies using tetracycline- or macrolide-based antibiotics combined with topical corticosteroids consistently reduced grade ≥ 2 events. In capecitabine-induced HFS, both systemic and topical COX-2 inhibition significantly reduced grade ≥ 2 toxicity, while methylcobalamin showed phase III efficacy. For HFSR, barrier reinforcement, COX-2 inhibition, and high-potency corticosteroids were effective. Mechanism-based mapping revealed specific pathophysiological profiles: inflammatory–epithelial for EGFR rash, inflammatory–neuropathic for HFS, and mechanical–vascular–inflammatory for HFSR.SummaryDermatological toxicities associated with anticancer therapies show clear mechanistic divergence and require toxicity-specific preventive strategies. Rather than a one-size-fits-all approach, mechanism-driven and toxicity-specific supportive care represents the most rational and effective strategy for managing these adverse events.Keywords: Anticancer drug toxicity, EGFR inhibitors, Hand–foot syndrome, Hand–foot skin reaction, Supportive care, Dermatologic adverse events Introduction Anticancer therapies have substantially improved survival outcomes across multiple malignancies. However, dermatological toxicities remain among their most frequent and clinically impactful adverse events. Cutaneous reactions are not merely cosmetic complications since they significantly impair patients’ quality of life (QOL). For example, hand–foot syndrome (HFS) markedly reduces QOL and functional status in patients receiving fluoropyrimidines [1]. Similarly, dermatological toxicities associated with epidermal growth factor receptor (EGFR) inhibitors negatively affect health-related QOL, psychosocial well-being, and daily activities [2]. Furthermore, these toxicities may cause dose modification, treatment interruption, or discontinuation, potentially compromising oncologic efficacy of drugs. EGFR inhibitors commonly induce acneiform rash, pruritus, xerosis, and paronychia. Multikinase inhibitors (MKIs)—including sorafenib, sunitinib, regorafenib, cabozantinib, and lenvatinib—are commonly associated with hand–foot skin reactions (HFSR), whereas fluoropyrimidines such as capecitabine frequently cause HFS. Although these toxicities differ in their clinical presentation and pathophysiology, they substantially affect patient-reported outcomes and treatment adherence. Over the past two decades, numerous clinical studies have evaluated preventive and therapeutic strategies for anticancer drug-induced dermatological toxicities. In EGFR inhibitor-associated rash, preemptive strategies combining oral tetracyclines and topical corticosteroids have been widely adopted following randomized studies such as the STEPP trial [3], and current clinical practice guidelines recommend prophylactic oral minocycline or doxycycline with topical corticosteroids [4]. However, there is conflicting evidence regarding the efficacy of prophylactic topical corticosteroids; some trials have questioned their advantages [5], whereas more recent studies evaluating strategies without routine prophylactic corticosteroids have reported positive outcomes [6], suggesting potential shifts in management paradigms. Similarly, in fluoropyrimidine-induced HFS, recent randomized trials have demonstrated the preventive efficacy of topical diclofenac [7] and prophylactic topical corticosteroids [8], indicating a possible paradigm shift toward anti-inflammatory preemptive approaches. These evolving findings highlight the uncertainty in the field and suggest that optimal preventive strategies may differ across drug classes and toxicity types. Despite the increase in clinical research studies, reviews have largely focused on individual drug classes or specific toxicities, limiting the comprehensive understanding of evolving preventive and therapeutic strategies across anticancer agents. Hence, a cross-drug evaluation is required to clarify evidence patterns, identify inconsistencies, and map areas of consensus and discrepancy. Therefore, this scoping review aimed to systematically map the clinical studies evaluating preventive and therapeutic interventions for anticancer drug-induced dermatological toxicities, including acneiform rashes, pruritus, paronychia, xerosis, HFS, and HFSR. Methods Study Design This scoping review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extensions for Scoping Reviews (PRISMA-ScR) guidelines. The methodological framework proposed by Arksey and O’Malley, and further refined by Levac et al., was followed to systematically identify, select, and map relevant evidence. Initial screening was performed by one reviewer (Y.I.), and a second reviewer (S.K.) independently screened the studies and confirmed the extracted data. Eligibility Criteria Eligibility criteria were defined using the Population–Concept–Context (PCC) framework. Population Study population comprised adult patients with cancer receiving anticancer drug therapy, including EGFR inhibitors (monoclonal antibodies and tyrosine kinase inhibitors), multikinase inhibitors (sorafenib, sunitinib, regorafenib, cabozantinib, and lenvatinib), and fluoropyrimidines. Concept Clinical studies evaluating preventive or therapeutic interventions for anticancer drug-induced dermatological toxicities, including acneiform rash, pruritus, paronychia, xerosis, HFS, and HFSR were included. Context Clinical research settings, including randomized controlled trials (RCTs), prospective studies, and retrospective clinical studies, were included. Inclusion and Exclusion Criteria Studies were included if they: (1) evaluated preventive (preemptive/prophylactic) or therapeutic (reactive/management) interventions; (2) reported clinical outcomes related to dermatological toxicities; (3) were RCTs, prospective cohort studies, or retrospective clinical studies; (4) were published in peer-reviewed journals; and (5) were written in English. Studies were excluded if they: (1) were case reports, case series with fewer than 10 patients, conference abstracts, reviews, editorials, or expert opinions; (2) did not evaluate a specific intervention; (3) focused solely on pathophysiology without clinical outcome data; or (4) exclusively involved pediatric populations. Information Sources and Search Strategy A comprehensive literature search was conducted in PubMed/MEDLINE for studies published from database inception to December 2025. The search strategy combined terms related to: (1) drug classes (e.g., “EGFR inhibitor,” “cetuximab,” “erlotinib,” “sorafenib,” “regorafenib,” and “capecitabine”); (2) dermatologic toxicities (e.g., “rash,” “pruritus,” “hand–foot syndrome,” “hand–foot skin reaction,” “paronychia,” and “xerosis”); and intervention concepts (e.g., “prophylaxis,” “prevention,” “treatment,” and “management”). Study Selection All identified records were imported into the reference management software and duplicates were removed. Two reviewers independently screened the titles and abstracts for eligibility, followed by full-text assessment of potentially relevant articles. Discrepancies were resolved by discussion and consensus. The study selection process is illustrated in a PRISMA flow diagram in Fig. 1. PRISMA flow diagram illustrating the study selection process. A total of 1550 records were identified through database searching. After removing the duplicates, 940 records were obtained, which were subjected to title and abstract screening; of these, 830 records were excluded. A total of 110 full-text articles were assessed for eligibility, and 59 were excluded for predefined reasons. In total, 51 studies met the inclusion criteria and were subjected to qualitative synthesis (26 addressing EGFR inhibitor-associated dermatologic toxicities and 25 addressing HFS/HFSR) Data Charting Process A standardized data extraction form was developed and pilot-tested to collect relevant data from the selected studies. The following data were extracted: author and publication year; country/region; study design; cancer type; drug class and specific agent; type of dermatologic toxicity; preventive or therapeutic strategy; comparator (if applicable); primary and secondary outcomes; and key findings. Data Synthesis Extracted data were descriptively summarized and mapped according to: (1) drug class, (2) type of dermatologic toxicity, (3) preventive vs. therapeutic strategy, and (4) study design. No formal risk-of-bias assessment was performed, as the objective of this scoping review was to map the breadth and characteristics of the available evidence rather than to evaluate the quality of individual studies. Results Mapping of Clinical Interventions for EGFR Inhibitor-associated Dermatologic Toxicities A total of 26 clinical studies that evaluated preventive or therapeutic interventions for EGFR inhibitor-associated dermatological toxicities were included. Most of these studies were RCTs, including phase III studies, indicating a relatively well-developed evidence base. Acneiform rash was the most frequently investigated toxicity, followed by pruritus and paronychia (Table 1). Table 1EGFR inhibitor-associated dermatologic interventions (n = 26)RefStudy designCancer / RegimenToxicityInterventionComparatorPrimary endpointKey outcomeRegion[12]Double-Blind-RCTmCRC / CetuximabRashMinocycline 100 mg/day (8 weeks) + tazarotene 0.05% creamPlaceboTotal face lesion count at 8 weeksSignificant reduction in facial lesion count at weeks 1–4; no significant difference at week 8USA[3]Phase II RCTmCRC / PanitumumabRashProphylactic moisturizer + sunscreen + hydrocortisone 1% + doxycycline 100 mg BIDReactive treatment ≥ G2 skin toxicity29 vs. 62%USA[11]Double-Blind-RCTMixed EGFRIRashTetracycline 500 mg BIDPlacebo ≥ G2 rashNo significant differenceUSA[20]PilotEGFR biologicsPruritusAprepitant 125/80/80 mgNoneVAS reduction91% of patients responded to aprepitantItaly[15]Pilot studymCRC / CetuximabRashVitamin K1 0.1% BIDHistoricalG3 incidence15% (lower vs. historical)Italy[9]RCTmCRC / PanitumumabRashProphylactic moisturizer + hydrocortisone 0.5% + minocycline 100 mgReactive treatment ≥ G2 toxicity21 vs. 62%Japan[27]Retrospective studyPC / ErlotinibRashMinocycline prophylaxisDeferred minocycline treatmentRash incidence47.7 vs. 80.8%Japan[18]Phase II studyNSCLC / ErlotinibRashEGF ointment 1 ppm BIDNoneResponse rate69% responseKorea[28]Retrospective studymCRC / PanitumumabRashMinocycline 100 mg/dayReactive ≥ G2 rash44 vs. 84.6%Japan[13]Phase III RCTNSCLC / ErlotinibRashMinocycline 100 mg BIDReactive/NoneRash incidenceNo G3 incidence changeCanada[16]Double-Blind-RCTmCRC / CetuximabRashVit K1 + doxycyclineVehicle ≥ G2 rashNo incidence differenceGermany[23]Retrospective studyNSCLC / EGFR-TKIRashNSAIDs (loxoprofen)Non-NSAID groupHazard ratio of rash onsetHR 0.149Japan[14]Double-Blind-RCTmCRC / EGFR mAbRashTopical doxycycline 4%VehicleSeverity of rashLowered moderate-severe rashIsrael[29]Phase II RCTEGFRIRashAdapalene 0.1%PlaceboLesion countNo significant differenceJapan[19]Double-Blind Phase III studyEGFRIRashEGF ointment (1 vs. 20 ppm)PlaceboResponse77.8 vs. 44.4%Korea[21]Double-Blind-RCTEGFRIPruritusOrvepitant 10/30 mgPlaceboNRS changeNo significant differenceItaly/UK[17]Double-Blind-RCTmCRC / EGFR mAbRashVit K1 0.1% BIDPlaceboLesion ratioNo significant differenceJapan[25]Cohort studyNSCLC / EGFR-TKIParonychiaBetaxolol 0.25% BIDNo prophylaxis3-months incidence20 vs. 58%Taiwan[10]Phase III RCTmCRC / PanitumumabRashClarithromycin 200 mg BIDSkin care only ≥ G2 rash21.3 vs. 54.7%Japan[30]Phase III RCTmCRC / EGFR mAbFacial rashRanking-down group that started with a very strong corticosteroid and serially ranked down every 2 weeks unless facial acneiform eruption exacerbatedRanking-up group that started with a weak corticosteroid and serially ranked up at exacerbation ≥ G2 facial acneiform eruptionNo significant differenceJapan[31]RCTEGFR-IRashProphylactic treatment with honeysuckleConventional treatment with minocycline ≥ G2 rash56.5% vs. 71.7%China[26]Case series studyEGFR-TKIParonychiaTimolol 0.5% + antibioticNoneORR83% responseTaiwan[24]Cohort studymCRC / PanitumumabRashNSAIDsNo NSAID ≥ G2 rash78 vs. 90.7%; OR 0.2Japan[22]Double-Blind-RCTNSCLC / EGFR-TKIPruritusAprepitant vs. desloratadineActive comparator ≥ 50% VAS reduction53 vs. 24%China[5]RetrospectivemCRC / EGFR mAbRashMinocycline + topical steroidMinocycline alone ≥ G2 overallNo significant differenceJapan[6]Phase II RCTEGFR-mut NSCLCDermatologic adverse eventsOral doxycycline or minocycline (100 mg twice daily; weeks 1–12), clindamycin 1% (on scalp daily; weeks 13–52), chlorhexidine 4% (on fingernails and toenails daily), and ceramide-based moisturizer (on body and face at least daily)Standard of care ≥ G2 dermatologic adverse events42 vs. 75%Global ≥ G2, Grade 2 or higher toxicity according to CTCAE (Severity reduction indicates decrease in grade distribution without change in overall incidence); DAE, Dermatologic adverse event; OR, Odds ratio (HR reported as provided in original study). Cohort/retrospective studies adjusted for confounders where stated EGFR inhibitor-associated dermatologic interventions (n = 26) ≥ G2, Grade 2 or higher toxicity according to CTCAE (Severity reduction indicates decrease in grade distribution without change in overall incidence); DAE, Dermatologic adverse event; OR, Odds ratio (HR reported as provided in original study). Cohort/retrospective studies adjusted for confounders where stated Comprehensive Tetracycline- or Macrolide-based Prophylactic Regimens Multicomponent prophylactic strategies that combine systemic tetracyclines (minocycline, tetracycline, or doxycycline) with topical corticosteroids and skin barrier care have demonstrated the most consistent reductions in moderate-to-severe dermatological toxicities. In the STEPP trial [3], grade ≥ 2 skin toxicities decreased from 62% in the reactive management group to 29% in the preemptive group. Similarly, the J-STEPP study [9] reported a reduction in grade ≥ 2 toxicities from 62.5 to 21.3%. A phase III randomized trial of clarithromycin prophylaxis [10] reported reductions in grade ≥ 2 skin toxicities from 54.7 to 21.3%. Recently, the global COCOON trial [6] showed that enhanced prophylactic dermatologic management reduced grade ≥ 2 adverse events from 75 to 42% without preventive topical corticosteroid administration. Tetracycline or Macrolide Monotherapy A randomized placebo-controlled trial of tetracycline [11] showed no significant reduction in grade ≥ 2 rash. A double-blind trial of minocycline [12] demonstrated significantly reduced facial lesion counts during weeks 1–4, but no sustained effect at week 8. In the Pan-Canadian Rash Trial [13], minocycline did not significantly reduce the overall incidence of rash, although a reduction in grade 3 events was observed (12 to 28%). Topical Antibiotic Strategies A double-blind randomized trial of topical doxycycline 4% foam [14] demonstrated a reduction in moderate-to-severe rash severity, although the overall incidence reduction was not clearly determined. Vitamin K–based Modulation of EGFR Signaling Topical vitamin K-based strategies yielded inconsistent results. A pilot study [15] suggested reduced occurrence of grade 3 rashes compared with historical controls. However, in the EVITA trial [16], vitamin K1 showed no reduction in grade ≥ 2 rash incidence, although severity scores improved. A subsequent double-blind randomized study [17] found no significant benefits. Repair-oriented Therapy (Epidermal Growth Factor-based Approaches) A phase II study of epidermal growth factor (EGF) ointment [18] reported a 69% response rate in patients with established rash. A subsequent phase III randomized trial [19] demonstrated a dose-dependent response, with 77.8% response rate in the high-dose EGF group compared to that of 44.4% in the placebo group (p = 0.042). However, these studies were not designed with adequately powered sample sizes. Neurokinin-1 Receptor Antagonists for Pruritus Three studies evaluated the use of neurokinin-1 (NK1) receptor antagonists for EGFR-TKI-associated pruritus. A single-arm pilot study on aprepitant [20] demonstrated substantial symptom reduction. A placebo-controlled randomized trial of orvepitant [21] demonstrated no superiority over the placebo. In contrast, a double-blind randomized trial comparing aprepitant with desloratadine [22] showed significantly higher response rates with aprepitant (53 vs. 24%). Anti-inflammatory Modulation with NSAIDs Two retrospective cohort studies evaluated the use of NSAIDs for EGFR inhibitor-associated rash. In EGFR-TKI-treated patients [23], NSAID co-administration was associated with reduced risk of rash (adjusted Hazard Ratio [HR], 0.149). Similarly, in patients with panitumumab-treated colorectal cancer [24], the use of NSAIDs reduced grade ≥ 2 rash incidence (78% vs. 90.7%; Odds Ratio [OR], 0.2). Topical β-blockers for Paronychia Paronychia-specific strategies have been studied less frequently. Prophylactic topical betaxolol [25] reduced the incidence of paronychia from 58 to 20%. Treatment with topical timolol combined with antibiotics [26] achieved an 83% overall response rate in established lesions. Mechanism × Outcome Matrix (EGFR Inhibitor-associated Dermatologic Toxicities) Interventions were categorized according to primary mechanism and mapped against outcome type (Fig. 2). Multi-component tetracycline- or macrolide-based strategies demonstrated the most consistent reduction in grade ≥ 2 dermatological toxicities, as supported by multiple randomized trials [3, 6, 9, 10]. In contrast, tetracycline or macrolide monotherapy exhibited limited reductions in overall incidence but modest effects on severity, particularly in high-grade events [12, 13]. Similarly, topical antibiotic approaches primarily reduced severity rather than incidence [14]. Vitamin K-based interventions showed inconsistent results, with no reproducible reduction in grade ≥ 2 toxicity [16, 17]. EGF-based repair-oriented therapies were effective for established lesions in phase II and III trials [18, 19], whereas NK1 receptor antagonists showed drug-specific variability in pruritus control [21, 22]. Observational data suggested a potential role for NSAIDs in reducing rash incidence across EGFR inhibitor classes [23, 24], and that topical β-blockers were beneficial for periungual toxicities [25, 26]. Overall, the matrix highlights that multi-component prophylactic regimens yielded the most robust incidence reduction, whereas single-mechanism approaches produced selective severity modulation or variable therapeutic responses more frequently. Mechanism × outcome matrix of clinical interventions for EGFR inhibitor-associated dermatologic toxicities. This heatmap summarizes the distribution and relative strength of the evidence for preventive and therapeutic strategies targeting EGFR inhibitor-related dermatological adverse events. The horizontal axis represents intervention categories based on clinical strategy, including minocycline/tetracycline/doxycycline combined with topical corticosteroids, antibiotic monotherapy (minocycline/tetracycline/doxycycline), topical antibiotics, vitamin K-based therapy, epidermal growth factor (EGF)-mediated repair, neurokinin-1 (NK1) receptor antagonists, non-steroidal anti-inflammatory drugs (NSAIDs), β-adrenergic blockers, and topical retinoids. The vertical axis represents outcome categories: reduction in incidence of grade ≥ 2 toxicities, reduction in severity without clear incidence reduction, demonstrated treatment efficacy for established toxicities, and interventions with negative or inconclusive results. Color intensity reflects the relative strength of the clinical evidence (0 = no evidence; 1 = weak or inconsistent evidence; 2 = moderate evidence; and 3 = strong evidence, supported by phase III randomized trials). Comprehensive antibiotic-based prophylactic regimens combined with topical corticosteroids consistently demonstrated reductions in moderate-to-severe dermatologic events, whereas single-mechanism approaches frequently showed selective severity modulation or inconsistent findings. Repair-oriented strategies (EGF-based therapy) demonstrated strong therapeutic efficacy for established toxicities Mapping of Clinical Interventions for Capecitabine-induced HFS A total of 17 clinical studies that evaluated preventive strategies for capecitabine-induced HFS were included (Table 2). Mechanism-based mapping revealed clear differences in therapeutic efficacy across intervention categories (Fig. 3). Table 2Clinical interventions for capecitabine-induced HFS (n = 17)ReferenceStudy designInterventionComparatorPrimary endpointKey outcomeMechanism[51]Retrospective studyCelecoxib 200 mg BIDHistoricalHFS incidence ≥ G2 HFS occurred after 6 months was 17%COX-2 inhibition[32]Phase II RCTCelecoxib 200 mg BIDNone ≥ G2 HFSReduced incidence (30 vs. 11.8%)COX-2 inhibition[33]Phase III RCTCelecoxib 200 mg BIDNone ≥ G2 HFSReduced incidence (29.6 → 14.7%)COX-2 inhibition[52]Double blind pilot RCTTopical celecoxib 1%Placebo ≥ 1 grade improvementNo significant differenceTopical COX-2[7]Phase III DB-RCTTopical diclofenac 1%Placebo ≥ G2 HFSReduced incidence (15.0 vs. 3.8%)Topical COX-2[8]Phase IITopical hydrocortisone 0.1%Historical ≥ G2 (4 cycles) ≥ G2 HFS occurred in 6.4% of patientsAnti-inflammatory[34]Phase III DB-RCTMethylcobalaminPlacebo ≥ G2 HFSReduced incidence (29.1 vs. 14.5%)Neuroprotective[36]Phase III DB-RCTPyridoxine 200 mgPlacebo ≥ G2 HFSNo differenceVitamin B6[37]Double blind-RCTPyridoxine 100 mgPlaceboHFS incidenceNo significant differenceVitamin B6[38]Phase III Double blind-RCTPyridoxine 200 mgPlacebo ≥ G2 HFSNo significant differenceVitamin B6[39]Phase II RCTPyridoxine 60 mgNoneTime to onset of ≥ G2 HFSNo significant differenceVitamin B6[40]Phase III Double blind-RCTUrea + lactic acidPlacebo ≥ Moderate HFSNo significant differenceKeratolytic[41]Phase III RCTMapisal ointmentUreaHFS incidenceNo significant differenceAntioxidant[42]Phase III Double blind-RCTStructured teachingStandard care ≥ G2 HFSNo significant differenceEducation[35]Double blind-RCTEVOSKIN creamPlaceboHFS incidenceReduced incidence (56.8 vs. 75.9%)Lithium-based barrier[43]Phase II RCTTJ-28 (Kampo)Pyridoxine ≥ G2 HFSNo significant differenceHerbalCapecitabine-induced HFS refers to fluoropyrimidine-associated palmar–plantar erythrodysesthesia graded according to the CTCAE criteria. Incidence reduction denotes statistically significant decreases in grade ≥ 2 events, whereas severity reduction reflects shifts in grade distribution without consistent incidence reduction. COX-2 inhibition includes systemic and topical anti-inflammatory strategies; neuroprotective modulation refers to the use of vitamin B12 derivatives; barrier strategies encompass moisturizing or lithium-based formulations; and metabolic modulation refers to pyridoxine-based interventions Clinical interventions for capecitabine-induced HFS (n = 17) Capecitabine-induced HFS refers to fluoropyrimidine-associated palmar–plantar erythrodysesthesia graded according to the CTCAE criteria. Incidence reduction denotes statistically significant decreases in grade ≥ 2 events, whereas severity reduction reflects shifts in grade distribution without consistent incidence reduction. COX-2 inhibition includes systemic and topical anti-inflammatory strategies; neuroprotective modulation refers to the use of vitamin B12 derivatives; barrier strategies encompass moisturizing or lithium-based formulations; and metabolic modulation refers to pyridoxine-based interventions Mechanism × outcome matrix of clinical interventions for capecitabine-induced hand–foot syndrome (HFS). This heatmap summarizes the distribution and relative strength of the clinical evidence for preventive and therapeutic strategies targeting capecitabine-associated HFS. The horizontal axis represents intervention categories based on the proposed biological mechanisms, including oral and topical NSAIDs, topical corticosteroids, neuroprotective modulation (methylcobalamin), lithium-based barrier reinforcement, vitamin B6 (pyridoxine), keratolytic strategies, antioxidant formulations, structured educational interventions, and herbal medicine (TJ-28). The vertical axis represents the outcome categories: reduction in the incidence of grade ≥ 2 HFS, reduction in severity without consistent incidence reduction, and interventions with no demonstrated benefit. Color intensity reflects the relative strength of the clinical evidence (0 = no evidence; 1 = weak or limited evidence; 2 = moderate evidence; and 3 = strong evidence, supported by phase III randomized trials). Both systemic and topical NSAIDs demonstrated the most consistent reduction in moderate-to-severe HFS. Neuroprotective modulation with methylcobalamin also showed a significant reduction in incidence in a phase III trial. In contrast, vitamin B6, keratolytic formulations, antioxidant ointments, and structured educational interventions consistently failed to demonstrate preventive efficacy across randomized trials NSAIDs and Anti-inflammatory Strategies In a randomized phase II study, celecoxib reduced the incidence of grade ≥ 2 HFS from 30 to 11.8% [32]; this benefit was further confirmed in a subsequent phase III randomized trial, in which grade ≥ 2 HFS was reduced from 29.6% to 14.7% [33]. Topical diclofenac treatment yielded similar results. In the D-TORCH phase III trial, topical diclofenac reduced grade ≥ 2 HFS from 15.0% to 3.8% [7]. Neuroprotective Modulation A multicenter, double-blind phase III trial demonstrated that oral methylcobalamin reduced grade ≥ 2 HFS from 29.1% to 14.5% [34]. Topical Corticosteroids A phase II study of prophylactic topical hydrocortisone reported a low incidence of grade ≥ 2 HFS (6.4%) within four cycles [8], supporting an inflammatory mechanism, although confirmatory randomized data remain limited. Lithium-based Barrier Modulation A double-blind, randomized study of a lithium-containing moisturizing formulation demonstrated a reduction in severe HFS [35], although its effects on overall incidence were modest. Interventions without Demonstrated Benefit Vitamin B6 (pyridoxine) showed no reduction in grade ≥ 2 HFS across four randomized trials [36–39]. Keratolytic agents (including urea and lactic acid) were also ineffective for moderate-to-severe HFS in a phase III trial [40]. Antioxidant ointment (Mapisal) showed no superiority over urea [41]. Structured educational interventions were also ineffective in reducing grade ≥ 2 HFS in a phase III trial [42]. A phase II randomized trial of TJ-28 (a Kampo medicine) also failed to demonstrate preventive efficacy [43]. Mechanism × Outcome Matrix (Capecitabine-induced HFS) The mechanism × outcome matrix for capecitabine-induced HFS (Fig. 3) indicates that NSAIDs—both systemic and topical—provide the strongest and most consistent reduction in the incidence of grade ≥ 2 HFS. Neuroprotective modulation using methylcobalamin also demonstrated significant benefits in a phase III trial. In contrast, metabolic modulation (vitamin B6), keratolytic approaches, antioxidant formulations, and structured educational strategies were consistently ineffective in reducing clinically significant HFS across several randomized trials. Overall, this matrix suggests that capecitabine-induced HFS is predominantly driven by inflammatory and neuropathic mechanisms rather than by abnormalities in keratinization or metabolic pathways. Mapping of Clinical Interventions for Multikinase Inhibitor-associated HFSR Eight clinical studies that evaluated preventive strategies against multikinase inhibitor-associated HFSR were included (Table 3). Mechanism-based mapping revealed a multifactorial therapeutic landscape that differed from that of fluoropyrimidine-associated HFS (Fig. 4). Table 3Clinical interventions for multikinase inhibitor-associated HFSR (n = 8)ReferenceStudy designInterventionComparatorPrimary endpointKey outcomeMechanism[47]Phase II RCTHydrocolloid dressingUrea cream ≥ G2 HFSRReduced incidence (29 vs. 69%)Friction reduction[44]Phase III RCT10% Urea (TID)Best supportive careAny-grade HFSRReduced incidence (56 vs. 74%)Barrier reinforcement[45]Double blind-RCT10% Urea (BID)MoisturizerIncidence densityNo significant differenceBarrier[46]Double blind pilotUrea (secondary)PlaceboNew HFSRNo significant differenceBarrier[48]Phase III RCTCelecoxib 200 mg BIDNone ≥ G2 HFSRReduced incidence (63.8 vs 29.3%)COX-2 inhibition[49]Phase II RCTClobetasol (preemptive)ReactiveAbsence HFSRReduced incidence (30 vs 13%)High-potency steroid[50]Phase IIAluminum chloride 30%NoneG3 HFSRG3 HFSR occurred in 7.4% of patientsSweat suppression[34]Double blind-RCTTDX105 + ureaPlaceboAny-grade HFSRReduced incidence (76.1 vs. 53.8%)Herbal anti-inflammatoryMultikinase inhibitor-associated HFSR refers to a distinct dermatological toxicity predominantly observed with vascular endothelial growth factor receptor (VEGFR)-targeting multikinase inhibitors such as sorafenib, regorafenib, and sunitinib. HFSR is characterized by localized hyperkeratotic painful lesions in pressure-bearing or friction-prone areas that are often accompanied by erythema, blistering, and callus formation. Grade classifications were based on the CTCAE criteria unless otherwise specified. “Incidence reduction” indicates a statistically significant decrease in grade ≥ 2 HFSR compared with that of control groups. “Absence of HFSR” was defined as the proportion of patients without clinically detectable lesions during the predefined assessment period. “Barrier reinforcement” includes topical keratolytic or urea-based strategies aimed at improving epidermal integrity. “Friction reduction” refers to mechanical offloading interventions such as hydrocolloid dressings. “COX-2 inhibition” includes systemic anti-inflammatory agents (e.g., celecoxib). “High-potency steroid” denotes topical corticosteroids used preemptively. “Sweat suppression” refers to eccrine gland-targeted approaches (e.g., aluminum chloride). “Herbal anti-inflammatory” indicates multi-component botanical formulations targeting inflammatory signaling pathways Clinical interventions for multikinase inhibitor-associated HFSR (n = 8) Multikinase inhibitor-associated HFSR refers to a distinct dermatological toxicity predominantly observed with vascular endothelial growth factor receptor (VEGFR)-targeting multikinase inhibitors such as sorafenib, regorafenib, and sunitinib. HFSR is characterized by localized hyperkeratotic painful lesions in pressure-bearing or friction-prone areas that are often accompanied by erythema, blistering, and callus formation. Grade classifications were based on the CTCAE criteria unless otherwise specified. “Incidence reduction” indicates a statistically significant decrease in grade ≥ 2 HFSR compared with that of control groups. “Absence of HFSR” was defined as the proportion of patients without clinically detectable lesions during the predefined assessment period. “Barrier reinforcement” includes topical keratolytic or urea-based strategies aimed at improving epidermal integrity. “Friction reduction” refers to mechanical offloading interventions such as hydrocolloid dressings. “COX-2 inhibition” includes systemic anti-inflammatory agents (e.g., celecoxib). “High-potency steroid” denotes topical corticosteroids used preemptively. “Sweat suppression” refers to eccrine gland-targeted approaches (e.g., aluminum chloride). “Herbal anti-inflammatory” indicates multi-component botanical formulations targeting inflammatory signaling pathways Mechanism × outcome matrix of interventions for multikinase inhibitor-associated HFSR. Interventions are categorized based on the proposed mechanisms (horizontal axis) and mapped against outcome type (vertical axis: incidence reduction, severity reduction, or no significant benefit). Color intensity reflects the relative strength of the evidence (0 = none; 1 = limited; 2 = phase II; and 3 = phase III). Barrier reinforcement (urea-based strategies), COX-2 inhibition, and preemptive high-potency corticosteroids demonstrated the most consistent reductions in clinically significant HFSR Barrier Reinforcement Strategies Barrier reinforcement using intensive urea-based formulations demonstrated strong evidence for incidence reduction. A multicenter, phase III trial demonstrated that prophylactic application of 10% urea cream three times daily significantly reduced any-grade HFSR (73.6% to 56.0%) and grade ≥ 2 events (29.2% to 20.7%) [44]. Conversely, a double-blind randomized trial employing twice-daily urea application showed no benefit for HFSR incidence reduction [45]. Similarly, in a secondary prophylaxis setting during sunitinib therapy, twice-daily urea was not superior to placebo [46]. Friction Reduction Mechanical offloading through hydrocolloid dressings significantly reduced progression to grade ≥ 2 HFSR in a randomized phase II study, with incidence decreasing from 69% in the urea arm to 29% in the dressing arm [47]. COX-2 Inhibition Systemic COX-2 inhibition has demonstrated consistent benefits. In a phase III randomized trial, celecoxib reduced grade ≥ 2 HFSR from 63.8% to 29.3% and grade 3 events from 19.0 to 3.4% [48]. High-potency Corticosteroids Preemptive use of high-potency topical corticosteroids, such as clobetasol, significantly increased the proportion of patients without HFSR during the first two cycles of regorafenib therapy (30% vs. 13%) [49]. Sweat Suppression A prospective phase II trial of topical aluminum chloride demonstrated a low incidence of grade 3 HFSR (7.4%) compared to that of historical rates (~ 20%), suggesting a potential benefit in reducing severe events [50]. Herbal Anti-inflammatory Modulation A double-blind randomized trial of TDX105 topical soaking solution significantly reduced the overall incidence of HFSR (76.1% to 53.8%), grade 3 events (19.6% to 7.7%), and delayed onset of HFSR (median, 25 vs. 11 days) during regorafenib therapy [34]. Mechanism × Outcome Matrix (Multikinase Inhibitor-associated HFSR) The mechanism × outcome matrix for multikinase inhibitor-associated HFSR (Fig. 4) demonstrated that barrier reinforcement (with adequate dosing), systemic COX-2 inhibition, and high-potency corticosteroids provided the most consistent reductions in clinically significant HFSR. Friction reduction and sweat suppression strategies further support the roles of mechanical and eccrine factors in disease development. Collectively, these findings indicate that HFSR arises from the interplay between mechanical stress, epidermal barrier dysfunction, and inflammatory signaling, mechanistically distinguishing it from capecitabine-induced HFS. Discussion Principal Findings This scoping review systematically mapped the clinical evidence for preventive and therapeutic strategies against three major anticancer drug-induced dermatological toxicities: EGFR inhibitor-associated rash, capecitabine-induced HFS, and MKI-associated HFSR. Despite the overlapping clinical manifestations and shared impact on QOL and treatment adherence, mechanism × outcome mapping revealed a clear divergence in therapeutic responsiveness and underlying pathophysiology. For EGFR inhibitor-associated rash, comprehensive tetracycline- or macrolide-based prophylactic strategies consistently reduced grade ≥ 2 dermatologic toxicities across multiple randomized trials [3, 6, 9, 10]. By contrast, antibiotic monotherapy has modest or inconsistent effects [11–13]. Repair-oriented approaches using EGF have demonstrated therapeutic benefits in established lesions [18, 19], while vitamin K-based strategies have failed to show reproducible preventive efficacy [16, 17]. Neurokinin-1 receptor antagonism demonstrated drug-specific variability in pruritus control [21, 22]. The evidence profile differed. NSAIDs demonstrated consistent and reproducible reductions in grade ≥ 2 HFS in both phase II and phase III trials [32, 33]. Topical diclofenac significantly reduced clinically meaningful HFS in a large phase III study [7] with independent confirmation in a Japanese phase III trial [53], thus strengthening its external validity. Neuroprotective modulation with methylcobalamin also reduced grade ≥ 2 HFS in a multicenter phase III trial [34], suggesting a neuropathic component. In contrast, pyridoxine failed to demonstrate benefits in four randomized trials [36–39], and keratolytic, antioxidant, herbal, and structured educational interventions consistently showed no preventive efficacy [40–43]. In patients with MKI-associated HFSR, preventive strategies reflect multifactorial disease models. Barrier reinforcement using intensive urea-based application reduced the incidence of HFSR in a phase III trial [44], whereas lower-frequency or secondary prophylaxis was ineffective [45, 46]. Systemic COX-2 inhibition significantly reduced grade ≥ 2 HFSR [48]. Preemptive high-potency corticosteroids reduce early HFSR events [49], hydrocolloid dressings mitigated progression [47], sweat suppression reduces severe events [50], and herbal anti-inflammatory modulation significantly reduces both the incidence and severity [34]. Collectively, these findings suggest that HFSR arises from the interactions between mechanical stress, epidermal barrier dysfunction, vascular alterations, and inflammatory signaling. Mechanistic Divergence Across Toxicities Integrated mapping underscores the fact that superficially similar dermatological toxicities require fundamentally different preventive approaches. EGFR inhibitor-associated rash is best mitigated by comprehensive anti-inflammatory and barrier-oriented prophylaxis. Capecitabine-induced HFS predominantly responds to inflammation and neuropathic modulation. MKI-associated HFSR requires barrier reinforcement, combined with anti-inflammatory strategies and mechanical stress reduction. These differences challenge the common practice of applying uniform supportive care strategies across drug classes. Incidence Reduction vs. Severity Modulation An important distinction emerged between interventions that reduce the incidence of grade ≥ 2 events and those that primarily modulate severity. Comprehensive EGFR prophylaxis and COX-2 inhibition in HFS reduced clinically meaningful toxicity rates. In contrast, specific strategies, such as vitamin K for EGFR rash or low-frequency urea for HFSR, primarily influence severity or hydration parameters without reducing the overall incidence. Given that grade ≥ 2 events often drive dose reduction or treatment interruption, incidence reduction may represent the more clinically relevant endpoint. Evolving Landscape and Persistent Gaps Recent guideline updates [54, 55] have incorporated evidence-based prophylactic strategies for EGFR inhibitors and anti-inflammatory approaches for HFS. However, substantial gaps exist in the literature. First, several trials were stratified by concurrent exposure to immune checkpoint inhibitors (ICI). Emerging data [56] suggest that immune-mediated skin toxicity may overlap with or modify targeted therapy-related dermatological events. As combination regimens have become standard, the interaction between chemotherapy-, targeted-, and immune-related skin toxicities remains poorly characterized. Second, optimal combinations of mechanism-based strategies remain undefined. Whether combined COX-2 and neuroprotective approaches yield additive benefits for HFS has not been prospectively evaluated. For HFSR, the relative contribution of barrier reinforcement to the anti-inflammatory modulation requires further mechanistic clarification. Third, most trials did not incorporate biomarker stratification or predictive modeling, thereby limiting personalized prophylaxis. Importantly, certain historically adopted practices, most notably vitamin B6 for HFS, continue to lack supporting evidence despite multiple negative randomized trials [36, 38]. Limitations This scoping review has limitations. First, the study did not include a formal risk-of-bias assessment or quantitative meta-analysis due to the nature of the review. Second, heterogeneity in grading criteria, endpoints, and prophylactic regimens limited direct cross-study comparisons. Finally, several positive findings were obtained from single-center or phase II studies, requiring further confirmation in larger trials. Conclusions Mechanism-based mapping revealed a clear divergence in preventive and therapeutic responsiveness across EGFR inhibitor-associated rashes, capecitabine-induced HFS, and multikinase inhibitor-associated HFSR. Although recent evidence supports the use of structured prophylaxis and anti-inflammatory strategies, substantial knowledge gaps persist, particularly in the context of combination immunotherapies. Future supportive care approaches should be toxicity-specific, mechanism-driven, and prospectively validated within contemporary oncological treatment paradigms. Key References Santhosh A, Sharma A, Bakhshi S et al. (2024) Topical diclofenac for prevention of capecitabine-associated hand–foot syndrome: A double-blind randomized controlled trial. J Clin Oncol 42:1821–1829. 10.1200/JCO.23.01730○ This phase III trial is the first to demonstrate the safety and efficacy of inexpensive topical diclofenac in preventing capecitabine-associated HFS. Furthermore, it suggests that effective HFS prevention can improve the treatment intensity of capecitabine by reducing dose modifications. Santhosh A, Sharma A, Bakhshi S et al. (2024) Topical diclofenac for prevention of capecitabine-associated hand–foot syndrome: A double-blind randomized controlled trial. J Clin Oncol 42:1821–1829. 10.1200/JCO.23.01730○ This phase III trial is the first to demonstrate the safety and efficacy of inexpensive topical diclofenac in preventing capecitabine-associated HFS. Furthermore, it suggests that effective HFS prevention can improve the treatment intensity of capecitabine by reducing dose modifications. ○ This phase III trial is the first to demonstrate the safety and efficacy of inexpensive topical diclofenac in preventing capecitabine-associated HFS. Furthermore, it suggests that effective HFS prevention can improve the treatment intensity of capecitabine by reducing dose modifications. ○ This phase III trial is the first to demonstrate the safety and efficacy of inexpensive topical diclofenac in preventing capecitabine-associated HFS. Furthermore, it suggests that effective HFS prevention can improve the treatment intensity of capecitabine by reducing dose modifications. Xia Y, Zhu Y, Ling L et al. (2025) Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: Multicentre, double blind, randomised, placebo controlled, phase 3 trial. BMJ 390:e084290. 10.1136/bmj-2025-084290○ This phase III trial is the first to demonstrate the preventive efficacy of oral methylcobalamin for capecitabine-induced HFS, offering a cost-effective and highly safe intervention. These findings provide a new supportive care option, and subsequent confirmatory studies are eagerly awaited to solidify its role in clinical practice. Xia Y, Zhu Y, Ling L et al. (2025) Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: Multicentre, double blind, randomised, placebo controlled, phase 3 trial. BMJ 390:e084290. 10.1136/bmj-2025-084290○ This phase III trial is the first to demonstrate the preventive efficacy of oral methylcobalamin for capecitabine-induced HFS, offering a cost-effective and highly safe intervention. These findings provide a new supportive care option, and subsequent confirmatory studies are eagerly awaited to solidify its role in clinical practice. ○ This phase III trial is the first to demonstrate the preventive efficacy of oral methylcobalamin for capecitabine-induced HFS, offering a cost-effective and highly safe intervention. These findings provide a new supportive care option, and subsequent confirmatory studies are eagerly awaited to solidify its role in clinical practice. ○ This phase III trial is the first to demonstrate the preventive efficacy of oral methylcobalamin for capecitabine-induced HFS, offering a cost-effective and highly safe intervention. These findings provide a new supportive care option, and subsequent confirmatory studies are eagerly awaited to solidify its role in clinical practice. Author Contributions Y. Iimura conceived the study design. S. Kuroda conducted the review and wrote the manuscript. All authors discussed the results and contributed to the final manuscript. All authors have read and approved the final version of this manuscript. Funding Open Access funding provided by The University of Tokyo. This work was supported by the Practical Research for Innovative Cancer Control Project grant (No. 24ck0106978h0001) from the Japan Agency for Medical Research. Data Availability No datasets were generated or analysed during the current study. Declarations Ethics Approval This study is a scoping review of published literature and does not require ethical approval, as it does not involve the collection of new primary data or direct interaction with human participants. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.